Laserfiche WebLink
Epidiolex (Cannabidiol) in Tx Resistant Epilepsy <br />MODEL DISEASE <br />AFFECTED "MODE" Plasticity <br />THERAPEUTIC CONTROL Synaptic control <br />A it <br />Anti- <br />inflammatiT <br />Cell cycle <br />�1 <br />Cell death <br />control <br />A A <br />0% <br />1996 <br />z99a <br />-30% <br />- <br />-50% <br />- <br />70% <br />60% <br />Fig. 1: Median % Reduction in Total Seizures <br />Week 4 Week 8 Week 12 Week 16 Week 24 <br />Fig 2. 50% Responder Analysis -Total Seizures <br />wN k4 vVee[Z wt!&12 w+ k16 We k24 <br />510% <br />40% <br />30% <br />20% <br />10% <br />Total Patients aOmet Patients Non-Dravet Patents <br />rn <br />N <br />Devinsky O et al., Poster presented at the 2015 Annual Meeting of the America <br />Epilepsy Society. Funded by GW Pharmaceuticals, the company developing Epidiolex <br />